$6,210.24 speaking Payment -- Sanofi to Dr. Ashley Nelson

Sanofi Compensates Rheumatologist Dr. Ashley Nelson for Skyrizi Speaking Engagement

This page provides a detailed analysis of a $6,210.24 speaking payment from Sanofi to Dr. Ashley Nelson. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$6,210.24
Payment Typespeaking
Payment NatureCompensation for serving as faculty or as a speaker
Pharmaceutical CompanySanofi
PhysicianDr. Ashley Nelson
NPI Number1578490507
Physician SpecialtyRheumatology
LocationCity, WI
Date of Payment2025-11-03
Related Drug/DeviceSkyrizi
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Sanofi made a $6.2K speaking payment to Ashley Nelson, a Rheumatology specialist in City, WI. The payment was associated with Skyrizi. Sanofi paid Dr. Ashley Nelson $6,210.24 on November 3, 2025, for speaking services related to Skyrizi. The payment was for serving as faculty or a speaker, a common engagement for pharmaceutical companies to educate healthcare professionals. This specific payment falls within the typical range for speaking engagements in the pharmaceutical industry, especially for specialized drugs like Skyrizi.

Patient Guidance: What This Payment Means for You

Patients should be aware that their healthcare providers may receive compensation from pharmaceutical companies for educating others about specific medications. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for speaking engagements are common in the pharmaceutical industry, particularly for drugs targeting specific conditions like those treated by rheumatologists. The amount is moderate for such services.

Regulatory Context: Sunshine Act Requirements

This payment is subject to reporting under the Sunshine Act, requiring disclosure of transfers of value from drug and device manufacturers to physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

What was this $6.2K payment for?

This was a speaking payment of $6.2K from Sanofi to Ashley Nelson, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Skyrizi. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Ashley Nelson accept pharmaceutical money?

Yes, Ashley Nelson received this $6.2K payment from Sanofi. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Ashley Nelson's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this speaking payment?

A speaking payment of $6.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Rheumatology?

To compare this payment against Rheumatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rheumatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Ashley Nelson's relationship with Sanofi?

The payment amount of $6,210.24 is specifically for speaking services. This $6.2K speaking payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Rheumatology?

The engagement is tied to the drug Skyrizi, indicating a focus on a particular therapeutic area.

What should patients do after learning about this payment?

Patients should be aware that their healthcare providers may receive compensation from pharmaceutical companies for educating others about specific medications.

What else should I know about this speaking payment?

The payment date is in the future (November 3, 2025), which is unusual for reported data and may indicate a placeholder or future commitment.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.